Medscape (7/5, Swift Yasgur , Subscription Publication) reported, “Early in-hospital administration of long-acting injectable (LAI) antipsychotics following a first admission for schizophrenia is linked to a significantly lower risk for hospital readmission, new research suggested.” Researchers “found that readmission rates increased in those who received LAIs with early discontinuation and decreased among their counterparts who received LAIs without early discontinuation compared with patients not receiving LAIs.” The findings were published in JAMA Network Open.

Related Links:

— Medscape (requires login and subscription)

The Washington Post (7/3, Ovalle ) reported, “Public health experts and officials are amplifying their warnings about the risks of unregulated and sometimes illegal products advertised on social media and easily purchased online or in vape shops.” Some of these products “claim to contain the hallucinogenic mushroom compound psilocybin, which is legal for use in two states but illegal federally.” And “some products contain potentially harmful synthetic chemicals or extracts from a sometimes-toxic mushroom known as amanita muscaria.”

Related Links:

— “The Washington Post (requires login and subscription)

MedPage Today (7/2, Kahn) reports, “Older adults who experienced delirium while hospitalized for COVID-19 had increases in functional disability and cognitive impairment in the 6 months after discharge, according to a prospective cohort study.” In the study, patients “with delirium had increased functional disability (rate ratio 1.32, 95% CI 1.05-1.66) and cognitive impairment (odds ratio 2.48, 95% CI 1.38-4.82) over the 6 months after discharge compared with those without in-hospital delirium, reported” researchers in JAMA Network Open.

Related Links:

— MedPage Today (requires login and subscription)

Healio (7/2, Jenkins) reports, “Youth with autism spectrum disorder and psychiatric comorbidities were more likely to be hospitalized and show greater symptom severity, which led to prolonged hospital stays and higher costs, according to study results.” In the study, “results showed patients with ASD and comorbid impulse control disorders had the highest likelihood of psychiatric hospitalization (OR = 7.2; 95% CI, 6.47-8.07), followed by disruptive behavior disorders (OR = 2.5; 95% CI, 2.2-2.77) and mood disorders (OR = 2.2; 95% CI, 1.99-2.41).” These findings were presented at the American Psychiatric Association Annual Meeting.

Related Links:

— “Psychiatric comorbidities increase odds of hospitalization among youth with ASD,”Cassandra Jenkins, Healio, July 2, 2024

MedPage Today (7/1, DePeau-Wilson ) reports, “Multiple first-line antidepressant medications were broadly linked with weight gain, although bupropion (Wellbutrin) had the least amount of weight change, according to observational data.” In a two-year study, “the estimated weight gain was lower for bupropion compared with sertraline (Zoloft) – the most commonly prescribed antidepressant in the analysis – at 6 months (difference -0.80 kg, 95% CI -1.26 to -0.42 kg), according to” researchers. Additionally, six-month weight gain was higher for “escitalopram (Lexapro): difference 0.41 kg (95% CI 0.31-0.52 kg); paroxetine (Brisdelle): difference 0.37 kg (95% CI 0.20-0.54 kg); duloxetine (Cymbalta): difference 0.34 kg (95% CI 0.22-0.44 kg); venlafaxine (Effexor): difference 0.17 kg (95% CI 0.03-0.31 kg);” and “citalopram (Celexa): difference 0.12 kg (95% CI 0.02-0.23 kg)” than bupropion. These results were published in Annals of Internal Medicine.

Related Links:

— MedPage Today (requires login and subscription)